<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02541292</url>
  </required_header>
  <id_info>
    <org_study_id>H-15009760</org_study_id>
    <nct_id>NCT02541292</nct_id>
  </id_info>
  <brief_title>Muscle Inflammation and Fat Infiltration in Patients Affected by FSHD</brief_title>
  <official_title>Muscle Inflammation and Fat Infiltration in Patients Affected by FSHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Facioscapulohumeral muscular dystrophy (FSHD) is the second most common muscular dystrophy
      with approximately 500 patients in Denmark. It is characterized by weakness and wasting of
      the facial muscles, the muscles in the shoulder region and of the legs.

      The primary aim of this study is to investigate possible links and order between inflammation
      and fat infiltration in the muscles in patients with FSHD.

      Approximately 15 patients with FSHD will be recruited for repeated MRI-scans during a year
      where the inflammation and fat infiltration in the muscles can be quantified.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle inflammation</measure>
    <time_frame>One MRI scan per subject (exam lasts approximately 60 min.)</time_frame>
    <description>MRI (t2 mapping) will be used to quantify the inflammation in skeletal muscle.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle fat fraction</measure>
    <time_frame>One MRI scan per subject (exam lasts approximately 60 min.)</time_frame>
    <description>The Dixon MRI will be used to quantify the fat fraction in skeletal muscle.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>One muscle strength test per subject (exam lasts approximately 60 min.)</time_frame>
    <description>Isokinetic muscle dynamometry will be used to measure muscle strength.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">10</enrollment>
  <condition>Facioscapulohumeral Muscular Dystrophy 1a</condition>
  <arm_group>
    <arm_group_label>Patient group</arm_group_label>
    <description>Patients over 18 years old with confirmed FSHD (facioscapulohumeral muscular dystrophy).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention, observational</intervention_name>
    <arm_group_label>Patient group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Persons in Denmark diagnosed with FSHD is invited to the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed FSHD

        Exclusion Criteria:

          -  All contraindications for undergoing an MRI scan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Copenhagen Neuromuscular Center</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>September 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <last_update_submitted>August 31, 2018</last_update_submitted>
  <last_update_submitted_qc>August 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Julia Dahlqvist, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Facioscapulohumeral</mesh_term>
    <mesh_term>Myositis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

